© 1999 by European Society of Cardiology
The Atrial Pacing Peri-ablation for Paroxysmal Atrial Fibrillation (PA3) Study
Rationale and study design
Division of Cardiology, Foothills Hospital and The University of Calgary Calgary, Alberta, Canada
The Canadian Atrial Pacing Peri-Ablation for Paroxysmal Atrial Fibrillation Study tested the hypotheses that atrial pacing prevents paroxysmal atrial fibrillation (PAF) in patients without symptomatic bradycardia and that DDDR pacing is more likely to prevent PAF following total atrioventricular (AV) node ablation compared to VDD pacing. Patients with PAF who were refractory to or intolerant of antiarrhythmic drug therapy received a Medtronic Thera DR pacemaker 3 months prior to a planned total AV node ablation. Patients were randomized to atrial pacing or no pacing therapy. The time to first recurrence of sustained PAF was the primary study outcome event. Following AV node ablation, patients were randomized to the DDDR or VDD mode in a crossover study design. Patients were followed in each mode for 6 months. The time course of PAF recurrence was compared for each pacing mode.
Key Words: Paroxysmal atrial fibrillation, atrial pacing, dual chamber pacing, ventricular pacing, rate-responsive pacing
Correspondence: Anne M. Gillis, MD, FRCPC, Division of Cardiology, The University of Calgary, 3330 Hospital Drive N.W., Calgary, Alberta, Canada T2N 4N1.
[1] Kay GN, Babien RS, Epstein AE, Plumb VJ. Effect of catheter ablation of the atrioventricular junction on quality of life and exercise tolerance in paroxysmal atrial fibrillation. Am J Cardiol 1988; 62: 741–744.[CrossRef][Web of Science][Medline]
[2] Brignole L, Gianfranchi L, Menozzi C, et al. Assessment of atrio-ventricular junction ablation and DDDR mode-switching pacemaker versus pharmacological treatment in patients with severely symptomatic paroxysmal atrial fibrillation: a randomized controlled study. Circulation 1997; 96: 2617–2624.
[3] Darpö B, Walfridsson H, Aunes M, et al. Incidence of sudden death after radiofrequency ablation of the atrio-ventricular junction for atrial fibrillation. Am J Cardiol 1997; 80: 1174–1177.[CrossRef][Web of Science][Medline]
[4] Peters R, Wever E, Hauer R, Wittkampf F, Robles de Medina E. Bradycardia-dependent QT prolongation and ventricular fibrillation following catheter ablation of the atrioventricular junction with radiofrequency energy. J Am Coll Cardiol 1993; 21: 102–109.[Abstract]
[5] Gribbin GM, Bourke JP, McComb JM. Dual versus single chamber pacemakers in patients with paroxysmal atrial fibrillation treated with AV node ablation (Abstr). PACE 1997; 20: 1592.
[6] Rosenqvist M, Brandt J, Schüller HI. Long-term pacing in sinus node disease: Effects of stimulation mode on cardiovascular morbidity and mortality. Am Heart J 1988; 116: 16–22.[CrossRef][Web of Science][Medline]
[7] Sasaki Y, Shimotori M, Akahane K, et al. Long-term follow-up of patients with sick sinus syndrome: A comparison of clinical aspects among unpaced ventricular inhibited paced, and physiologically paced groups. PACE 1988; 11: 1575–1583.
[8] Stangl K, Seitz K, Wirtzfeld AHE, Blömer H. Differences between atrial single chamber (AAI) and ventricular single chamber pacing (VVI) with respect to prognosis and antiarrhythmic Effect in patients with sick sinus syndrome. Pacing Clin Electrophysiol 1990; 13: 2080–2085.[Medline]
[9] Santini M, Alexidou G, Ansalone G, Cecciatore G, Cini R, Turitto G. Relation of prognosis in sick sinus syndrome to age, conduction defects, and modes of permanent cardiac pacing. Am J Cardiol 1990; 65: 729–735.[CrossRef][Web of Science][Medline]
[10] Hesselson AB, Parsonnet V, Bernstein AD, Bonavita GJ. Deleterious Effects of long-term single-chamber ventricular pacing in patients with sick sinus syndrome: The hidden benefits of dual-chamber pacing. J Am Coll Cardiol 1992; 19: 1542–1549.[Abstract]
[11] Sgarbossa EB, Pinski SL, Maloney JD, et al. Chronic atrial fibrillation and stroke in paced patients with sick sinus syndrome: Relevance of clinical characteristics and pacing modalities. Circulation 1993; 88: 1045–1053.
[12] Andersen HR, Nielsen JC, Thomsen PEB, et al. Long-term follow-up of patients from a randomized trial of atrial versus ventricular pacing for sick-sinus syndrome. Lancet 1997; 350: 1210–1216.[CrossRef][Web of Science][Medline]
[13] Coumel P, Friocourt P, Mugica J, Attuel P, LeClercq J-F. Long-term prevention of vagal atrial arrhythmias by atrial pacing at 90/minute: Experience with 6 cases. PACE 1983; 6: 552–560.
[14] Attuel P, Pellerin D, Mugica J, Coumel P. DDD pacing: an effective treatment modality for recurrent atrial arrhythmias. PACE 1988; 11: 1647–1654.
[15] Mehra R and Hill MRS. Prevention of atrial fibrillation/flutter by pacing techniques. In Saksena S and Lüderitz B (Eds.). Interventional Electrophysiology: A Textbook 1996; 2nd edn Armonk, NY Futura Publishing Company Inc. pp. 521–40.
[16] Saksena S, Prakash A, Hill M, Krol RB, Munsif AN, Matthew PP, Mehra R. Prevention of recurrent atrial fibrillation with chronic dual-site right atrial pacing. J Am Coll Cardiol 1996; 28: 687–694.[Abstract]
[17] Murgatroyd F, Slade A, Nitzsche R, Camm AJ, Ritter P. for the Chorous Multicentre Study Group. A new pacing algorithm for the suppression of atrial fibrillation (Abstr). PACE 1994; 17: 863.
[19] Pritchett ELC, McCarthy EA, Wilkinson WE. Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias. A randomized, placebo-controlled, crossover trial in patients tolerating oral therapy. Ann Intern Med 1991; 114: 539–544.
[20] Anderson JL, Gilbert EM, Alpert BL, et al. Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind crossover study of flecainide and placebo with transtelephonic monitoring. Circulation 1989; 80: 1557–1570.
[21] Gillis AM, Connolly SJ, Yee R, et al. Atrial Pacing Periablation for Paroxysmal Atrial Fibrillation — Phase I. PACE 1998; 21: 872.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  W. de Voogt, N. van Hemel, P. de Vusser, G. H. Mairesse, R. van Mechelen, J. Koistinen, A. van den Bos, I. Roose, J. Voitk, S. Yli-Mayry, et al. No evidence of automatic atrial overdrive pacing efficacy on reduction of paroxysmal atrial fibrillation Europace, September 1, 2007; 9(9): 798 - 804. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Brignole, M. Gammage, L. Jordaens, R. Sutton, and on behalf of the Barcelona Discussion Group Report of a study group on ablate and pace therapy for paroxysmal atrial fibrillation Europace, January 1, 1999; 1(1): 8 - 13. [Abstract] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||